(Q36530118)

14 August 2017

1 reference

title

International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future (English)

1 reference

14 August 2017

0 references

2

Chi-Chao Chan

1 reference

14 August 2017

Robert B. Nussenblatt

series ordinal

1

object named as

Robert B Nussenblatt

1 reference

14 August 2017

3

Wyndham H Wilson

1 reference

14 August 2017

Jacob Hochman

4

1 reference

14 August 2017

Michael Gottesman

series ordinal

5

1 reference

14 August 2017

CNS and Ocular Lymphoma Workshop Group

series ordinal

6

1 reference

14 August 2017

1 June 2006

1 reference

Ocular Immunology and Inflammation

14 August 2017

1 reference

14 August 2017

14

1 reference

14 August 2017

3

1 reference

14 August 2017

139-144

1 reference

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Treatment of primary central nervous system lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Intraocular lymphoma: update on diagnosis and management

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Primary brain tumours in adults.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Ocular manifestations of central nervous system lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Primary intracerebral malignant lymphoma: report of 248 cases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

28 June 2018

Intraocular lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940600630170

New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2518223

Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas

21 September 2018

1 reference

12 December 2020

Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment

1 reference

12 December 2020

Immunocytochemical staining of vitreous cells. Indications, techniques, and results

1 reference

12 December 2020

Intraocular levels of methotrexate after intravenous administration

1 reference

12 December 2020

[Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma]

1 reference

12 December 2020

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

12 December 2020

Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement

1 reference

12 December 2020

Vitreous cytokine levels

1 reference

12 December 2020

10.1080/09273940600630170

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

16827214

1 reference